MX9701282A - Fenoles neuroprotectores. - Google Patents
Fenoles neuroprotectores.Info
- Publication number
- MX9701282A MX9701282A MX9701282A MX9701282A MX9701282A MX 9701282 A MX9701282 A MX 9701282A MX 9701282 A MX9701282 A MX 9701282A MX 9701282 A MX9701282 A MX 9701282A MX 9701282 A MX9701282 A MX 9701282A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- piperidinyl
- hydrogen
- chroman
- dementia
- Prior art date
Links
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- MGSHXMOLUWTMGP-UHFFFAOYSA-N 3'-carboxy-alpha-chromanol Chemical group C1=CC=C2C(O)CCOC2=C1 MGSHXMOLUWTMGP-UHFFFAOYSA-N 0.000 abstract 1
- -1 8-azabicyclo(3.2.1)octanyl Chemical class 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical class 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical class 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Esta invencion se refiere a compuestos de la formula (I) o sus sales de adicion de ácidos aceptables farmacéuticamente, en la que: (a) R2 y R5 se toman separadamente y R1, R2, R3 y R4 son cada uno independientemente hidrogeno, alquilo de (C1-C6), halo, CF3, OH u OR7 y R5 es metilo o etilo; o (b) R2 y R5 se toman juntos, formando un anillo de croman-4-ol; R1, R3 y R4 son cada uno independientemente hidrogeno, alquilo de (C1-C6), halo, CF3, OH u OR7; y R6 es un derivado de piperidinilo, pirrolidinilo u 8-azabiciclo (3.2.1)octanilo substituido; con la salvedad de que (a) cuando R2 y R5 se tomen separadamente, al menos uno de R1, R2, R3 y R4 no sea hidrogeno; y b) cuando R2 y R5 se tomen juntos, al menos uno de R1, R3 y R4 son cada uno independientemente hidrogeno, alquilo de (C1-C6), halo, CF3, OH u OR7; y R6 es un derivado de piperidinilo, pirrolidinilo u 8-azabiciclo(3.2.1)octanilo substituido; con la salvedad de que (a) cuando R2, R y R5 se tomen separadamente, al menos uno de R1, R2, R3 y R4 no sea hidrogeno; y (b) cuando R1 y R5 se toman juntos, al menos uno de R1, R3 y R4 no sea hidrogeno; sus composiciones farmacéuticas, y procedimientos de tratamiento de mamíferos que sufren de ataque subito, trauma del cordon espinal, lesion cerebral traumática, demencia por infarto multiple, enfermedades degenerativas del SNC, tales como enfermedad de Alzheimer, demencia senil de tipo Alzheimer, enfermedad de Huntington, enfermedad de Parkinson, epilepsia, esclerosis lateral amiotrofica, dolor, demencia por SIDA; estados psicoticos, adicion a fármacos, migraña, hipoglucemia, estados ansiolíticos, incontinencia urinaria y un acontecimiento isquémico consecuencia de cirugía del SNC, cirugía a corazon abierto o cualquier procedimiento durante la funcion del sistema cardiovascular está comprometida, con un compuesto de la formula (I) anterior o una de sus sales aceptables farmacéuticamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29265194A | 1994-08-18 | 1994-08-18 | |
| PCT/IB1995/000380 WO1996006081A1 (en) | 1994-08-18 | 1995-05-18 | Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9701282A true MX9701282A (es) | 1997-05-31 |
Family
ID=23125592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9701282A MX9701282A (es) | 1994-08-18 | 1995-05-18 | Fenoles neuroprotectores. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6046213A (es) |
| EP (1) | EP0777652B1 (es) |
| JP (1) | JP2888988B2 (es) |
| KR (1) | KR100224961B1 (es) |
| CN (1) | CN1151130C (es) |
| AT (1) | ATE243679T1 (es) |
| AU (1) | AU684359B2 (es) |
| BR (1) | BR9503694A (es) |
| CA (1) | CA2197451C (es) |
| CO (1) | CO4410320A1 (es) |
| CZ (1) | CZ290988B6 (es) |
| DE (1) | DE69531154T2 (es) |
| DK (1) | DK0777652T3 (es) |
| ES (1) | ES2201106T3 (es) |
| FI (1) | FI970664A0 (es) |
| HU (1) | HUT77520A (es) |
| IL (1) | IL114892A (es) |
| MX (1) | MX9701282A (es) |
| MY (1) | MY116637A (es) |
| NO (1) | NO307563B1 (es) |
| NZ (1) | NZ284852A (es) |
| PE (1) | PE35696A1 (es) |
| PL (1) | PL318658A1 (es) |
| PT (1) | PT777652E (es) |
| RU (1) | RU2139857C1 (es) |
| TR (1) | TR199501030A2 (es) |
| TW (1) | TW318178B (es) |
| WO (1) | WO1996006081A1 (es) |
| ZA (1) | ZA956865B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA59341C2 (uk) * | 1995-08-11 | 2003-09-15 | Пфайзер, Інк. | (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат |
| US6784200B2 (en) | 2000-10-13 | 2004-08-31 | Bristol-Myers Squibb Pharma Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| CA2386049A1 (en) | 1999-10-15 | 2001-04-26 | Daniel S. Gardner | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| US6462575B1 (en) * | 2000-08-28 | 2002-10-08 | Micron Technology, Inc. | Method and system for wafer level testing and burning-in semiconductor components |
| EP1186303A3 (en) * | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| EP1674087A1 (en) | 2000-10-02 | 2006-06-28 | Pfizer Products Inc. | Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists |
| ZA200108038B (en) * | 2000-10-02 | 2003-04-01 | Pfizer Prod Inc | Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists. |
| IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| US20030232739A1 (en) * | 2001-08-15 | 2003-12-18 | Pfizer Inc. | Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist |
| US7381733B2 (en) | 2001-11-30 | 2008-06-03 | Neurosearch A/S | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases |
| WO2003062235A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| TW200306189A (en) | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| CA2530023A1 (en) * | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2005035522A1 (en) * | 2003-10-08 | 2005-04-21 | Pfizer Japan, Inc. | 1-‘2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists |
| US7671072B2 (en) * | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| US7713990B2 (en) * | 2005-01-13 | 2010-05-11 | Neurosearch A/S | 3,8-substituted 8-AZA-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors |
| RU2418786C2 (ru) * | 2006-06-21 | 2011-05-20 | Пирамал Лайф Сайнсиз Лимитед | Энантиомерно чистые производные флавона для лечения пролиферативных нарушений и способы их получения |
| US9351947B2 (en) | 2007-01-29 | 2016-05-31 | National Research Council Of Canada | Use of catecholamines and related compounds as anti-angiogenic agents |
| RU2418578C1 (ru) * | 2009-12-08 | 2011-05-20 | Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | ПРИМЕНЕНИЕ 4,7-ДИМЕТИЛ-2-(ПРОП-1-ЕНИЛ)-3,4,4a,5,8,8a-ГЕКСАГИДРО-2Н-ХРОМЕН-4,8-ДИОЛА В КАЧЕСТВЕ АНАЛЬГЕЗИРУЮЩЕГО СРЕДСТВА |
| US8648198B2 (en) | 2011-01-19 | 2014-02-11 | Cold Spring Harbor Laboratory | Phenylethanolamine-based NMDA receptor antagonists |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CN106727556B (zh) * | 2016-11-30 | 2017-10-20 | 鑫喆喆 | 一种治疗脑损伤的药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3294804A (en) * | 1961-01-27 | 1966-12-27 | Sterling Drug Inc | 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine |
| FR5733M (es) * | 1966-09-27 | 1968-01-22 | ||
| DE1670583A1 (de) * | 1967-11-02 | 1971-02-25 | Degussa | Neue Piperidinderivate |
| JPS5359675A (en) * | 1976-11-08 | 1978-05-29 | Yoshitomi Pharmaceut Ind Ltd | Aminoalcohol derivatives |
| FR2546166B1 (fr) * | 1983-05-19 | 1985-10-25 | Synthelabo | Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique |
| US4968678A (en) * | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
| US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US5272160A (en) * | 1989-05-17 | 1993-12-21 | Pfizer Inc | 2-piperidino-1-alkanol derivatives as antiischemic agents |
| WO1990014087A1 (en) * | 1989-05-17 | 1990-11-29 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as antiischemic agents |
| ES2098248T3 (es) * | 1989-05-17 | 1997-05-01 | Pfizer | Derivados de 2-piperidino-1-alcanoles como agentes antiisquemicos. |
| MX24433A (es) * | 1990-02-06 | 1993-05-01 | Pfizer | Derivados de 3-piperidino-1-cromanol y sus analogos y procedimiento para su preparacion |
| AU642994B2 (en) * | 1990-05-10 | 1993-11-04 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
| CZ390792A3 (en) * | 1991-04-18 | 1994-04-13 | Pfizer | Precursors of medicaments based on esters of phenolic 2-piperidino-1-alkanols, process of their preparation, intermediates and use |
| JP2731664B2 (ja) * | 1992-04-09 | 1998-03-25 | 和男 今井 | レール及びその製造方法 |
| US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
| US5352683A (en) * | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| IL112099A (en) * | 1993-12-23 | 1999-07-14 | Ortho Pharma Corp | N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them |
| FR2722497B1 (fr) * | 1994-07-13 | 1996-08-14 | Synthelabo | Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique |
| UA59341C2 (uk) * | 1995-08-11 | 2003-09-15 | Пфайзер, Інк. | (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат |
-
1995
- 1995-05-18 NZ NZ284852A patent/NZ284852A/en unknown
- 1995-05-18 RU RU97102362A patent/RU2139857C1/ru not_active IP Right Cessation
- 1995-05-18 PT PT95917443T patent/PT777652E/pt unknown
- 1995-05-18 JP JP8507895A patent/JP2888988B2/ja not_active Expired - Fee Related
- 1995-05-18 WO PCT/IB1995/000380 patent/WO1996006081A1/en not_active Ceased
- 1995-05-18 AU AU23511/95A patent/AU684359B2/en not_active Ceased
- 1995-05-18 EP EP95917443A patent/EP0777652B1/en not_active Expired - Lifetime
- 1995-05-18 CZ CZ1997474A patent/CZ290988B6/cs not_active IP Right Cessation
- 1995-05-18 AT AT95917443T patent/ATE243679T1/de not_active IP Right Cessation
- 1995-05-18 CN CNB951946439A patent/CN1151130C/zh not_active Expired - Fee Related
- 1995-05-18 CA CA002197451A patent/CA2197451C/en not_active Expired - Fee Related
- 1995-05-18 HU HU9702051A patent/HUT77520A/hu not_active Application Discontinuation
- 1995-05-18 PL PL95318658A patent/PL318658A1/xx unknown
- 1995-05-18 DE DE69531154T patent/DE69531154T2/de not_active Expired - Fee Related
- 1995-05-18 ES ES95917443T patent/ES2201106T3/es not_active Expired - Lifetime
- 1995-05-18 KR KR1019970701028A patent/KR100224961B1/ko not_active Expired - Fee Related
- 1995-05-18 US US08/776,715 patent/US6046213A/en not_active Expired - Fee Related
- 1995-05-18 MX MX9701282A patent/MX9701282A/es not_active IP Right Cessation
- 1995-05-18 DK DK95917443T patent/DK0777652T3/da active
- 1995-07-24 TW TW084107652A patent/TW318178B/zh active
- 1995-08-10 IL IL11489295A patent/IL114892A/xx not_active IP Right Cessation
- 1995-08-14 MY MYPI95002369A patent/MY116637A/en unknown
- 1995-08-15 PE PE1995276268A patent/PE35696A1/es not_active Application Discontinuation
- 1995-08-15 CO CO95036443A patent/CO4410320A1/es unknown
- 1995-08-17 BR BR9503694A patent/BR9503694A/pt not_active IP Right Cessation
- 1995-08-17 ZA ZA9506865A patent/ZA956865B/xx unknown
- 1995-08-18 TR TR95/01030A patent/TR199501030A2/xx unknown
-
1997
- 1997-02-17 NO NO970728A patent/NO307563B1/no unknown
- 1997-02-17 FI FI970664A patent/FI970664A0/fi not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9701282A (es) | Fenoles neuroprotectores. | |
| YU41103A (sh) | Farmaceutski preparati receptor agonista nmda | |
| RU97102362A (ru) | Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| WO2004056786A3 (en) | Pyrimidine derivates for the treatment of abnormal cell growth | |
| CA2413424A1 (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| PT1029853E (pt) | Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos | |
| MY133992A (en) | Muscarinic antagonists | |
| AU6487094A (en) | 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative | |
| CA2326076A1 (en) | Novel macrolides | |
| AU1171897A (en) | 1-methylcarbapenem derivatives | |
| EP1698618A4 (en) | BENZAMIDE DERIVATIVE | |
| HK1043590A1 (zh) | 毒蕈碱性拮抗物 | |
| MY128818A (en) | Ethanesulfonyl-piperidine derivatives | |
| HU911520D0 (en) | Process for producing spiro-dibenzo-suberane derivatives | |
| ECSP951511A (es) | Fenoles neuroprotectores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| MM | Annulment or lapse due to non-payment of fees |